Ed Furlong serves as Glytec’s Chief Executive Officer. His experience in operations and financial management spans more than 30 years. Prior to joining Glytec, Ed served as Chief Operating Officer and Chief Financial Officer at Kyruus, a leader in provider search and scheduling solutions for hospitals and health systems, where he was instrumental in shaping the business model, building the organization and increasing revenues elevenfold. Ed previously served in a similar capacity at Exa Corporation, maker of engineering simulation and visualization software, where he directed the company’s IPO, raised private equity and mezzanine debt financing, and achieved consistent growth and profitability. Earlier in his career, he served as a senior executive in the investment services industry for both Fidelity Strategic Investments and UAM Investment Services, where he spearheaded a wide range of start-ups and turnarounds, and participated on several corporate boards. Ed holds a bachelor of science in economics from The Wharton School at the University of Pennsylvania and a master of business administration from Harvard Business School.

John Beneke serves as Glytec's Chief Financial Officer. Prior to joining Glytec in 2012, John was the Chief Financial Officer for M.M. Dillon & Co., a boutique investment bank in Greenwich, CT. Prior to that, John spent 22 years at Morgan Stanley & Co. He was a Managing Director in the Finance Division supporting the Institutional Securities Business. John has held multiple senior operating roles, with experience in Institutional Equity, Capital Markets, Fixed Income Derivatives, and Investment Banking. He has also served a 2 year tour of duty as Head of Investor Relations. John is a Certified Public Accountant, and holds an M.B.A. degree from Rutgers University and a B.A. from Dickinson College.

Robby Booth serves as Glytec’s Senior Vice President of Research and Development, facilitating the company’s innovation programs, patent inventions and FDA clearances as well as multiple partnerships with vendors of complementary technologies. He has 20 years of experience in developing and commercializing disruptive solutions. Robby is one of Glytec’s founders and has been instrumental in advancing the company’s solutions for diabetes therapy management, including new models, algorithms and software-as-a-medical-device products for personalized digital therapeutics. He is an inventor of more than two dozen issued and allowed U.S. and international patents. Prior to joining Glytec, Robby was Vice President of Product Development at CoMed, where he was integral in building and managing design controls and overseeing activities to ensure compliance with medical device regulations.

Melanie Mabrey serves as Glytec’s Vice President of Clinical Practice. Melanie is an Acute Care Nurse Practitioner whose clinical practice and scholarship focuses on chronic illness, particularly in endocrinology and diabetes mellitus. Melanie previously served on the faculty of Duke University School of Nursing as an assistant professor, teaching primary care and diabetes in the nurse practitioner program. She has extensive clinical experience in care of the chronically ill patients. Since 2002 her practice has focused extensively on inpatient diabetes management at Duke University Medical Center, Division of Endocrinology. She established and served as the director of their Inpatient Endocrine Nurse Practitioner Program. In 2006, she started a new endocrine/diabetes service at Duke Regional Hospital and went on to serve as the associate medical director. Melanie’s doctoral project, publications, and numerous local, regional, national and international presentations focus on care of patients with diabetes across the continuum of care particularly inpatient management. She earned her BSN from East Carolina University in 1993 and her MSN from the University of South Carolina in 2001. She earned the Doctor of Nursing Practice degree from Duke University in 2012, with her doctoral project: Continuous Intravenous Insulin: An Evaluation in Bariatric Patients Outside of the Intensive Care Unit, published in Bariatric Nursing and Surgical Patient Care Journal. Melanie was inducted into Sigma Theta Tau in 1992, is a member of the North Carolina Nurses Association, the American Diabetes Association, the American Association of Diabetes Educators, the American Association of Clinical Endocrinologist, and was honored to be inducted as a Fellow of the American Association of Nurse Practitioners in 2014.

Raymie McFarland serves as Vice President of Quality Initiatives, a role in which he has directed or otherwise participated in more than 60 studies involving use of Glytec’s solutions, all of which have been published in medical journals and/or presented at scientific conferences. Raymie has more than 20 years of experience articulating the benefits of innovative, quality-oriented tools, technologies and processes to clinicians, administrators and senior executives at healthcare organizations throughout the country. Prior to joining Glytec, Raymie was President and Co-Founder of Mantra Healthcare Solutions. Earlier in his career, Raymie worked for many years at Sanofi, one of the world’s largest pharmaceutical companies, where he was instrumental in developing multiple programs aimed at improving the care of patients with diabetes, including industry-recognized quality improvement processes for inpatient glycemic management and transitions of care. While at Sanofi, Raymie received several national quality awards for inpatient programming, leadership and medical projects. Raymie has certifications from Society of Hospital Medicine, CMS Readmissions Programming, and Telehealth Remote Monitoring as well as Quality Lean Processing, Six Sigma, and Quality Institute.

Dr. Andrew Rhinehart currently serves as Chief Medical Officer of Glytec. Prior to joining the company in 2015, Dr. Rhinehart was in clinical practice for 20 years. He served for seven years as Program Director and diabetologist at Johnston Memorial Diabetes Care Center in Abington, Virginia, now part of Ballad Health, the region's largest health system. He also served as Physician Champion for the health system’s Inpatient Glycemic Control Initiative. Dr. Rhinehart received his doctorate degree from the University of Maryland School of Medicine and completed his residency at East Tennessee State University. Although trained in internal medicine, Dr. Rhinehart was inducted as a fellow of the American College of Endocrinology based on his expertise in the field of diabetology. He is a current member and past chair of the American Diabetes Association’s Primary Care Advisory Group, and has served previously on their Professional Practice and Prevention Committees. Dr. Rhinehart was the first physician board certified in advanced diabetes management (BC-ADM); he serves as a content expert for the BC-ADM Exam and sits on the BC-ADM Exam Oversight Committee. He is also a certified diabetes educator. Dr. Rhinehart has been awarded recognition from the National Committee for Quality Assurance Diabetes Physician Recognition program for providing high quality care to persons with diabetes from 2002 until leaving clinical practice in 2015. He participated on the 2012 and 2017 National Standards for Diabetes Self-Management Education and Support revision workgroups.

Paula LeClair serves as Glytec's Executive Director & General Manager, Outpatient. In the diabetes industry, her name is synonymous with transformation and innovation. Prior to joining Glytec, Paula was Head of Operations for Onduo, a joint venture of Sanofi and Verily (an Alphabet company), where she was instrumental in driving vision and best practices for the company's virtual diabetes clinic. Paula previously served as President, CEO and Board Member of Telcare, a medical device manufacturer backed by Sequoia Capital and Norwest Venture Partners. She was a founding member of Telcare -- recognized as one of the first to market an FDA-cleared cellular-enabled blood glucose meter -- and ultimately directed its successful acquisition by BioTelemetry. Earlier in her career, Paula served in various operations and finance roles with Insulet, 3COM, Cisco Systems and Sun Microsystems. She holds a Master of Healthcare Delivery Science from Dartmouth College, a Master of Business Administration from Bentley University, a Bachelor of Science in Mechanical Engineering from University of Notre Dame and a Bachelor of Arts in Engineering Physics from Saint Anslem College. She is also a member of the American Diabetes Association Community Leadership Board of New England.